Equities analysts predict that Cara Therapeutics Inc (NASDAQ:CARA) will report earnings of ($0.59) per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Cara Therapeutics’ earnings. The lowest EPS estimate is ($0.72) and the highest is ($0.49). Cara Therapeutics posted earnings per share of ($0.51) during the same quarter last year, which indicates a negative year over year growth rate of 15.7%. The firm is scheduled to announce its next earnings results on Tuesday, November 5th.

On average, analysts expect that Cara Therapeutics will report full-year earnings of ($2.32) per share for the current fiscal year, with EPS estimates ranging from ($2.57) to ($2.08). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.11) per share, with EPS estimates ranging from ($3.01) to ($1.09). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.03. Cara Therapeutics had a negative return on equity of 68.36% and a negative net margin of 420.97%. The firm had revenue of $5.21 million during the quarter, compared to analyst estimates of $5.14 million.

Several research analysts have recently issued reports on CARA shares. HC Wainwright reissued a “buy” rating and issued a $30.00 target price (down previously from $31.00) on shares of Cara Therapeutics in a research report on Monday, August 12th. Laidlaw increased their target price on Cara Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. Needham & Company LLC increased their target price on Cara Therapeutics from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. Piper Jaffray Companies increased their target price on Cara Therapeutics from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Finally, Zacks Investment Research lowered Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.94.

In related news, Director Jeffrey L. Ives sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.75, for a total transaction of $54,375.00. Following the completion of the transaction, the director now owns 8,500 shares of the company’s stock, valued at approximately $184,875. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Frederique Ph.D. Menzaghi sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $23.24, for a total value of $464,800.00. Following the transaction, the senior vice president now directly owns 99,886 shares of the company’s stock, valued at approximately $2,321,350.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 120,848 shares of company stock valued at $2,844,442. 5.80% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in Cara Therapeutics by 3.6% during the 2nd quarter. BlackRock Inc. now owns 2,864,551 shares of the biopharmaceutical company’s stock valued at $61,587,000 after buying an additional 98,241 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Cara Therapeutics by 10.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,800,339 shares of the biopharmaceutical company’s stock valued at $60,207,000 after buying an additional 266,749 shares in the last quarter. First Manhattan Co. increased its position in Cara Therapeutics by 97.5% during the 2nd quarter. First Manhattan Co. now owns 1,938,188 shares of the biopharmaceutical company’s stock valued at $41,671,000 after buying an additional 956,968 shares in the last quarter. Vanguard Group Inc. increased its position in Cara Therapeutics by 0.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,779,452 shares of the biopharmaceutical company’s stock valued at $38,258,000 after buying an additional 13,417 shares in the last quarter. Finally, ETF Managers Group LLC bought a new position in Cara Therapeutics during the 2nd quarter valued at approximately $20,490,000. 57.84% of the stock is owned by institutional investors.

Shares of NASDAQ:CARA traded up $0.72 during trading on Friday, hitting $23.35. The stock had a trading volume of 582,500 shares, compared to its average volume of 959,379. Cara Therapeutics has a 12 month low of $12.19 and a 12 month high of $27.55. The company has a market capitalization of $899.58 million, a PE ratio of -11.33 and a beta of 2.18. The firm’s fifty day moving average is $23.36 and its 200 day moving average is $19.78. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.04.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

See Also: What are convertible shares? 

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.